Navigation Links
Aerolef in Medical Technology

YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain

MISSISSAUGA, ON, May 02, 2007 /PRNewswire-FirstCall/ - YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced top-line results from its randomized, placebo-controlled Phase IIb trial of AeroLEF(TM) in o...

YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial

- Company Announces Lead Investigator for U.S. Trial - MISSISSAUGA, ON, July 11, 2007 /PRNewswire-FirstCall/ - YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced results of secondary endpoint data f...

YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB PRESENTATIONS TO BE MADE AT THE 100TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH AND EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY

..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...
Aerolef in Biological Technology

YM BIOSCIENCES' SUBSIDIARY RESOLVES PROPOSED ARBITRATION WITH ONCOSCIENCE AG

..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...

YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB

..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...

YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING

..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...

YM BIOSCIENCES REPORTS THIRD QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS

..., and was developed at the Center of Molecular Immunology. YM is developing aerolef for the treatment of moderate to severe acute pain. The product is differen...lly control the analgesia required for their differing intensities of pain. aerolef met all endpoints in a randomized Phase II trial and is currently being pre...

YM BIOSCIENCES ANNOUNCES FDA LIFTS CLINICAL HOLD ON AEROLEF(R) AND CLEARANCE OF A PHASE II CLINICAL TRIAL

... - Dr. Ali Raza To Lead Further Development Of aerolef As President Of aerolef Division - MISSISSAUGA, ON, June 19 /PRNewswire-...of the Phase II clinical development of AeroLEF. aerolef is being developed as a novel and effective approa...
Other Tags
(Date:9/19/2014)... HealthDay Reporter THURSDAY, Sept. ... stress and family conflicts before surgery may face a ... study suggests. Investigators found that patients with a ... times greater risk for complications compared to those with ... long known that patient quality of life is a ...
(Date:9/19/2014)... "I have difficulty putting in my eye contacts, ... skin around my eyes during the struggle," said an ... a more convenient method of performing this task." , ... easier, more sanitary method of putting in contact lenses. ... saves time and effort, and helps prevent wrinkles around ...
(Date:9/19/2014)... of Mayo Clinic have discovered a defect in a ... of toxic protein in the brains of Alzheimer,s ... between neurons both significant contributors to this type ... of Neuron , offers the potential ... or rescue this pathway," says the study,s lead investigator, ...
(Date:9/19/2014)... 19, 2014 Recently, Top10BestSEOHosting.com has ... that JustHost, IX Web Hosting and Bluehost are ... “As is known to most people, VPS (Virtual ... physical server computer into many servers, each of ... on someone’s own dedicated computer,” the manager of ...
(Date:9/19/2014)... 19, 2014 BCC Research reveals in ... GLOBAL MARKETS , the global market for human antifungal ... by 2018, with a five-year compound annual growth rate ... growing at a steady 3.8% CAGR. , Given the ... sales, coupled with the incidence of increasing mortality and ...
Breaking Medicine News(10 mins):Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3Health News:Mayo researchers reveal pathway that contributes to Alzheimer's disease 2Health News:Top10BestSEOHosting.com: JustHost is One of the Best VPS Suppliers in 2014 2Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 2Health News:Global Market for Human Antifungal Therapeutics to Reach Nearly $13.9 Billion in 2018; Over-The-Counter (OTC) Segment Growing At 3.8% CAGR 3
(Date:9/19/2014)... a newly discovered hadrosaur with a truly ... Rhinorex condrupus by paleontologists from North Carolina ... what is now Utah approximately 75 million years ... which translates roughly into "King Nose," was a ... hadrosaurs like Parasaurolophus and Edmontosaurus. Hadrosaurs are usually ...
(Date:9/19/2014)... A new resource unveiled today by researchers from ... College Dublin provides both experienced and aspiring researchers ... build, and operate robots made from soft, flexible ... printing, laser cutters, and other advances in manufacturing ... important field. Using principles drawn from conventional rigid ...
(Date:9/19/2014)... of Oklahoma biology professor will study the unique bioelectric ... could eventually benefit people,s health. The OU researcher ... energy required to produce the signals used to map ... signals at a rate of 500-600 discharges a second ... the electric fish are extreme, but necessary for survival. ...
Breaking Biology News(10 mins):New hadrosaur noses into spotlight 2Soft robotics 'toolkit' features everything a robot-maker needs 2
Other Contents